Eli Lilly, Abbisko Expand Drug Hunt With $1.9 Billion Research Pact - Eli Lilly (NYSE:LLY)

Abbisko Therapeutics signed a new Eli Lilly partnership worth up to $1.9 billion to develop novel medicines globally.

mercoledì 24 giugno 2026 New tab

411 words~2 min read

Abbisko Therapeutics Co., Ltd. on Tuesday announced a new strategic research collaboration and license agreement with Eli Lilly and Co. (NYSE:LLY) aimed at discovering and developing innovative medicines across multiple disease targets.

The partnership expands the relationship between the two companies as they seek to advance novel drug candidates with global potential by combining their respective strengths in drug discovery, research and development, and global drug development capabilities.

Eli Lilly, Abbisko Expand Drug Hunt With $1.9 Billion Research Pact - Eli Lilly (NYSE:LLY)

Eli Lilly, Abbisko Expand Drug Hunt With $1.9 Billion Research Pact - Eli Lilly (NYSE:LLY)

Other newsrooms on this story

Related reading

Lilly offers up to $1.9B in new drug discovery deal with Abbisko

Other newsrooms on this story

Related reading

Lilly offers up to $1.9B in new drug discovery deal with Abbisko

Abbisko Therapeutics Deepens R&D Collaboration with Lilly

Abbisko Teams Up With Lilly In Latest U.S.-China Pharma Collaboration

Lilly, Ascidian link up in RNA exon editing pact

Eli Lilly stock edges higher as company plans nearly $4 billion in vaccine deals

Eli Lilly Deepens Innovation Push Through New Biopharma Collaborations - Eli…